Research News and Research

RSS

Awards dedicated to those working to fight against depression

The Welcome Back Awards is now accepting nominations to honor those who work in the depression community. The Welcome Back Awards is a program established by Eli Lilly and Company to recognize outstanding achievements in the fight against depression and the stigma often associated with the illness.

25 Sep 2009

$4.5 million cost involved for MLSIC set up

The Michigan Economic Development Corp. (MEDC), Ann Arbor SPARK, Greater Wayne Economic Development Corporation and a private foundation have collaborated to create the Michigan Life Science and Innovation Center (MLSIC). MLSIC will connect well-funded, experienced entrepreneurs with business accelerator organizations and start-up life science companies.

25 Sep 2009

Cardiovascular disease: Major cause of death in Europe

Despite the decline of heart disease mortality registered in the past 30 years, cardiovascular disease (CVD) remains the N.1 killer in Europe and in the World. In the EU, experts reveal that striking disparities still exist between countries not only in terms of CVD incidence, but also with regard to national prevention policies.

25 Sep 2009

Senior chemist receives nation's highest award for achievement in science

Joanna Fowler, a senior chemist and Director of the Radiotracer Chemistry, Instrumentation and Biological Imaging Program at the U.S. Department of Energy's Brookhaven National Laboratory, will be awarded the National Medal of Science at a White House ceremony on October 7. She is one of nine researchers named by President Barack Obama to receive the nation's highest award for lifetime achievement in science.

25 Sep 2009

Students live with elder residents as part of the Learning by Living project

A geriatric training method pioneered by Marilyn R. Gugliucci, PhD, president of the Association for Gerontology in Higher Education (the educational branch of The Gerontological Society of America) has proved successful enough that she plans to implement it on a national level.

25 Sep 2009

Researchers develop molecule to confuse insects' ability to detect plants

Biotechnology and Biological Sciences Research Council (BBSRC)-funded research, published this week in Chemical Communications, describes how scientists have discovered molecules that could confuse insects' ability to detect plants by interfering with their sense of smell. This could reduce damage to crops by insect pests and contribute to food security.

25 Sep 2009

Researchers to use Intravenous Immune Globulin for slowing AD progression

Researchers from the Memory and Cognition Center at University Hospitals Case Medical Center will begin testing an intriguing new approach to slowing down the progression of Alzheimer's Disease (AD) using Intravenous Immune Globulin (IGIV), also known as gammaglobulin.

25 Sep 2009

PACTR: The first WHO endorsed trials registry in Africa

The Pan-African Clinical Trials Registry (PACTR) has been accepted as a primary clinical trials registry - the first World Health Organization (WHO) endorsed trials registry in Africa. This registry will feed data into the global WHO International Clinical Trials Registry Platform (ICTRP) search portal facilitating African representation in the global picture of planned, ongoing and completed clinical trials. The Registry is currently funded by the European and Developing Countries Clinical Trials Partnership (EDCTP) and coordinated by the South African Cochrane Centre (SACC) at the Medical Research Council (MRC).

25 Sep 2009

Research to improve the targeting of chemotherapeutic drugs to specific cells

Kenneth Longmuir, associate professor of physiology & biophysics, and Richard Robertson, professor of anatomy & neurobiology, used liposomes, small spheres (less-than 100 nanometer in diameter) of naturally-occurring lipid molecules, as "packages" for the cancer chemotherapeutic agent doxorubicin, and a small peptide molecule to "address" the package to the targeted tissue.

25 Sep 2009

Research to develop small-molecule drug that blocks excess iron absorption

Excess iron in the body, if left unchecked, can form toxic deposits in major organs leading to serious conditions including heart failure, diabetes, liver cirrhosis, arthritis, and even infertility. Iron overload can be a consequence of a genetically mutated gene known as hereditary hemochromatosis, or a consequence of red blood cell transfusions, required as life saving treatments, for patients with diseases such as thalassemia.

25 Sep 2009

NIH to award $348 million for investigators to speed the translation of research into improved health

The National Institutes of Health (NIH) announced today that it is awarding $348 million to encourage investigators to explore bold ideas that have the potential to catapult fields forward and speed the translation of research into improved health.

25 Sep 2009

Researchers study about abnormal gene functioning in mitochondria

Researchers are delving into abnormal gene function in mitochondria, structures within cells that power our lives. Mitochondria are the place where energy is generated from the most basic molecules of food. Because this function is essential to life, defects in mitochondria may affect a wide range of organ systems in humans and animals.

25 Sep 2009

Neuroscience professor receives Institutes of Health Director's New Innovator Award

Leon Reijmers, PhD, assistant professor of neuroscience at Tufts University School of Medicine in Boston, is one of 55 recipients of the National Institutes of Health Director's New Innovator Award. Reijmers is investigating the way memories are stored in the brain, specifically focusing on the proteins involved in long-term memory storage.

25 Sep 2009

Chemicals found in breast milk adversly affect the fetal testis

A comparison of breast milk samples from Denmark and Finland revealed a significant difference in environmental chemicals which have previously been implicated in testicular cancer or in adversely affecting development of the fetal testis in humans and animals. This finding is published today in the International Journal of Andrology.

25 Sep 2009

Current stem cell applications to be discussed at NJIT

Stem cell researcher Treena Livingston Arinzeh will discuss current stem cell applications at NJIT, including the regeneration of bone and cartilage for bone fracture and osteoarthritis treatments, spinal cord repair, and liver regeneration at NJIT's first Research Caf.

25 Sep 2009

Caliper Life Sciences unveils XenoLight Rediject reagents series at WMIC

Caliper Life Sciences, Inc., a leading provider of tools and services for drug discovery and life sciences research, today introduced a series of XenoLight Rediject reagents at the World Molecular Imaging Congress (WMIC) in Montreal, Canada. Rediject D-Luciferin Ultra is the latest in an expanding range of XenoLight reagents for Caliper's IVIS optical imaging systems.

25 Sep 2009

Children exposed to pesticides more susceptible to chilhood leukemia

Northern California Cancer Center (NCCC) research reveals that children exposed to agricultural pesticides applied near their home may experience an increased risk of the most common form of childhood leukemia.

25 Sep 2009

$10 million grant to Weill Cornell Institute from NIMH to study geriatric depression

The Weill Cornell Institute of Geriatric Psychiatry at NewYork-Presbyterian Hospital/Westchester Division announced today it has received the largest grant in its 20-year history. One of a handful awarded nationally, the new $10 million, five-year "Center Grant" from the National Institute of Mental Health (NIMH) will enable NewYork-Presbyterian/Weill Cornell investigators to advance their pioneering work in understanding the biological, medical, cognitive and psychosocial problems of depressed seniors.

25 Sep 2009

Neogen announces first-quarter results of fiscal 2010

Neogen Corporation announced today that its revenues for the first quarter of FY 2010, which ended Aug. 31, increased 12% from the previous year's first quarter to $32,347,000. First quarter net income increased 18% from the prior year's $3,733,000 to $4,395,000, or to $0.29 per share in the current year compared to the previous year's $0.25.

25 Sep 2009

iCo Therapeutics, CPDD sign collaboration development agreement

iCo Therapeutics Inc. (TSX-V: ICO) is pleased to announce that the company has signed a collaboration development agreement with The Consortium for Parasitic Drug Development (CPDD) for the research and development of iCo's oral drug delivery technology for the treatment of neglected diseases such as leishmaniasis and trypanosomiasis. Initial funding of USD $182,930 will be provided for formulation optimization for tropical conditions.

25 Sep 2009